The use of the Xience nanoTM coronary stent system for the treatment of small vessels coronary artery disease

Drug-eluting stents have proven long-term safety and effectiveness for the treatment of coronary artery disease especially due to their marked efficacy in reducing restenosis rates. Nevertheless, the rates of late and very late stent thrombosis, especially in first-generation systems, have raised some concerns. Moreover, percutaneous coronary intervention to small vessels (especially <2.5 mm) remains challenging. The Xience nanoTM drug-eluting stent system was developed to improve coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (length ≤28 mm) with reference vessel diameters of ≥2.25 to <2.50 mm. In this article, we describe the components of the Xience nano drug-eluting stent system presenting clinical data of this current stent.